Japan's IP court rejects Samsung attempt to block Regeneron patent notices
Japan’s Intellectual Property High Court confirmed that innovators can notify Japan’s drug regulators of potential patent conflicts without facing unfair competition liability, rejecting Samsung Bioepis’s attempt to block Regeneron’s communications during...To view the full article, register now.
Already a subscriber? Click here to view full article